Drug
Mgcd516
Mgcd516: highest development phase Phase 2, developed by Mirati Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Mirati Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| MGCD516 NCT02978859 | Phase 2 | Liposarcoma |
| MGCD516 NCT02219711 | Phase 1 | Advanced Cancer |
Latest
No recent events.
Follow Mgcd516 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.